MX338971B - Ratones de m-csf humanizada. - Google Patents

Ratones de m-csf humanizada.

Info

Publication number
MX338971B
MX338971B MX2013009406A MX2013009406A MX338971B MX 338971 B MX338971 B MX 338971B MX 2013009406 A MX2013009406 A MX 2013009406A MX 2013009406 A MX2013009406 A MX 2013009406A MX 338971 B MX338971 B MX 338971B
Authority
MX
Mexico
Prior art keywords
human
hematopoietic cells
classifications
vivo
mice
Prior art date
Application number
MX2013009406A
Other languages
English (en)
Other versions
MX2013009406A (es
Inventor
Andrew J Murphy
Sean Stevens
Chozhavendan Rathinam
Elizabeth Eynon
Markus Manz
Richard Flavell
George D Yancopoulos
Original Assignee
Inst Res Biomedicine Irb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Res Biomedicine Irb filed Critical Inst Res Biomedicine Irb
Publication of MX2013009406A publication Critical patent/MX2013009406A/es
Publication of MX338971B publication Critical patent/MX338971B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8536—Animal models for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)

Abstract

La presente invención se refiere a ratones genéticamente modificados comprendiendo una secuencia de ácido nucleico que codifica una proteína de M-CSF humana. También se proporcionan ratones genéticamente modificados comprendiendo una secuencia de ácido nucleico que codifica una proteína de M-CSF humana que han sido injertados con células humanas tales como células hematopoyéticas humanas, y métodos para hacer tales ratones injertados. Estos ratones encuentran uso en una variedad de aplicaciones, tales como en modelado de enfermedad inmune humana e infección de patógeno; en clasificaciones in vivo para gentes que modulan el desarrollo y/o actividad de células hematopoyéticas; por ejemplo, en un estado de salud o enfermedad; en clasificaciones in vivo para agentes que son tóxicos para células hematopoyéticas; en clasificaciones in vivo para gentes que previenen contra, mitigan o invierten los efectos tóxicos de agentes tóxicos sobre células hematopoyéticas; en clasificaciones in vivo de células hematopoyéticas humanas a partir de un individuo para predecir la sensibilidad de un individuo a una terapia de enfermedad, etc.
MX2013009406A 2011-02-15 2012-02-14 Ratones de m-csf humanizada. MX338971B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161442946P 2011-02-15 2011-02-15
PCT/US2012/025040 WO2012112544A2 (en) 2011-02-15 2012-02-14 Humanized m-csf mice

Publications (2)

Publication Number Publication Date
MX2013009406A MX2013009406A (es) 2013-12-16
MX338971B true MX338971B (es) 2016-05-06

Family

ID=46673120

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017011324A MX380588B (es) 2011-02-15 2012-02-14 Ratones de m-csf humanizada.
MX2013009406A MX338971B (es) 2011-02-15 2012-02-14 Ratones de m-csf humanizada.
MX2016001791A MX350385B (es) 2011-02-15 2012-02-14 Ratones de m-csf humanizada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017011324A MX380588B (es) 2011-02-15 2012-02-14 Ratones de m-csf humanizada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016001791A MX350385B (es) 2011-02-15 2012-02-14 Ratones de m-csf humanizada.

Country Status (17)

Country Link
US (5) US8847004B2 (es)
EP (3) EP2675271B1 (es)
JP (5) JP5834097B2 (es)
KR (6) KR102390850B1 (es)
CN (3) CN103547148B (es)
AU (1) AU2012217836B2 (es)
CA (1) CA2826714C (es)
DK (3) DK3375284T3 (es)
ES (3) ES2685790T3 (es)
FI (2) FI3375284T3 (es)
IL (7) IL227704A0 (es)
MX (3) MX380588B (es)
MY (1) MY162984A (es)
PT (3) PT4233537T (es)
RU (2) RU2577978C2 (es)
SG (3) SG10202008003VA (es)
WO (1) WO2012112544A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002988A1 (en) 2009-07-01 2011-01-06 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for severe combined immunodeficiency (scid)
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
PT4233537T (pt) 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
BR112014008529A2 (pt) 2011-10-28 2017-04-18 Regeneron Pharma il-6 humanizado e receptor de il-6
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
RU2642319C2 (ru) 2012-09-07 2018-01-24 Йель Юниверсити Генетически модифицированные, не принадлежащие к человеческому роду животные и способ их использования
PT3939423T (pt) 2012-11-05 2024-05-29 Regeneron Pharma Animais não humanos geneticamente modificados e métodos de utilização dos mesmos
EP3561050B1 (en) 2013-02-20 2021-12-08 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
CN103409468B (zh) * 2013-03-20 2015-08-12 中国科学院广州生物医药与健康研究院 一种免疫缺陷小鼠模型的建立方法
MX369747B (es) 2013-04-16 2019-11-20 Regeneron Pharma Modificación dirigida del genoma de rata.
CN105308021B (zh) 2013-06-17 2018-05-04 3M创新有限公司 用于制备胍基官能化单体的方法
KR102407354B1 (ko) 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
SI3138397T1 (sl) * 2013-10-15 2019-04-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
MX358206B (es) * 2013-11-19 2018-08-09 Regeneron Pharma Animales no humanos que tienen un gen humanizado de un ligando inductor de la proliferacion.
US20150143558A1 (en) * 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
NO2785538T3 (es) 2014-05-07 2018-08-04
MX379268B (es) 2014-05-19 2025-03-11 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
CN111118047B (zh) * 2014-05-30 2023-09-22 再生元制药公司 人源化二肽基肽酶iv(dpp4)动物
HUE064960T2 (hu) 2014-12-05 2024-04-28 Regeneron Pharma Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok
AU2015360667B2 (en) 2014-12-09 2021-09-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
CN107896479B (zh) 2015-04-13 2021-07-13 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法
CN105994125B (zh) * 2015-04-15 2019-05-17 中国科学院广州生物医药与健康研究院 一种评价免疫缺陷小鼠模型的免疫缺陷程度的方法
US20180289840A1 (en) * 2015-05-24 2018-10-11 Central Institute For Experimental Animals Method for Evaluating Hematological Toxicity of Drug Under Evaluation, and Model for Evaluating Hematological Toxicity of Drug Under Evaluation
CA2989839A1 (en) * 2015-06-23 2016-12-29 The Jackson Laboratory Non-hla matched humanized nsg mouse model with patient-derived xenograft
CN105145486A (zh) * 2015-07-22 2015-12-16 中国医学科学院医学实验动物研究所 Rag2基因敲除大鼠在建立个性化肿瘤治疗模型中的应用
EP3376857B1 (en) 2015-11-20 2021-02-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
ES2908669T3 (es) 2016-02-04 2022-05-03 Regeneron Pharma Animales no humanos que tienen un gen ANGPTL8 modificado genéticamente
KR101887051B1 (ko) * 2016-02-12 2018-08-10 한국과학기술원 오브젝트 탐닉행동을 활용한 동물행동 조절 방법
PT3422845T (pt) 2016-02-29 2021-08-26 Regeneron Pharma Roedores com um gene tmprss humanizado
JP7458185B2 (ja) * 2016-11-30 2024-03-29 ザ ジャクソン ラボラトリー 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル
WO2018195027A1 (en) 2017-04-17 2018-10-25 The Jackson Laboratory Method of determining toxicity of an immunomodulatory drug for use in humans
EP4276185A3 (en) 2017-09-29 2024-02-21 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
US11589562B2 (en) 2018-07-16 2023-02-28 Regeneran Pharmaceuticals, Inc. Mouse model of DITRA disease and uses thereof
WO2020041174A1 (en) * 2018-08-20 2020-02-27 The Jackson Laboratory Method of determining toxicity of an immunomodulatory drug
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111073907B (zh) * 2018-12-25 2025-07-29 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf1基因改造非人动物的构建方法及应用
IL286905B2 (en) 2019-04-04 2024-06-01 Regeneron Pharma Non-human animals containing the human coagulation factor 12 locus
KR20220016869A (ko) 2019-06-04 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법
BR112021022722A2 (pt) 2019-06-07 2022-01-04 Regeneron Pharma Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
US20220354098A1 (en) * 2019-07-17 2022-11-10 Yale University Genetically Modified Non-Human Animals and Methods of Use Thereof
JP2022553570A (ja) 2019-11-05 2022-12-23 アピール テクノロジー，インコーポレイテッド 植物生産物における感染の予測
KR20220133248A (ko) * 2020-01-28 2022-10-04 리제너론 파마슈티칼스 인코포레이티드 인간화 pnpla3 좌위를 포함하는 비-인간 동물 및 사용 방법
EP4216971A4 (en) 2020-09-24 2024-10-02 The Jackson Laboratory HUMANIZED MOUSE MODELS FOR EVALUATING CELLULAR IMMUNOTHERAPY
CN113100175B (zh) * 2021-03-08 2022-07-12 北京大学人民医院 一种巨细胞病毒感染的人源化小鼠模型及其构建方法
CN114853871B (zh) * 2021-04-20 2024-04-05 百奥赛图(北京)医药科技股份有限公司 Csf1和/或csf1r基因人源化的非人动物及其构建方法和应用
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5573930A (en) * 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
WO1988003173A2 (en) 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
EP0322240B1 (en) 1987-12-23 1995-03-01 The Board Of Trustees Of The Leland Stanford Junior University Chimeric immunocompromised mammals and their use
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
DK0438053T3 (da) 1990-01-15 1999-11-22 Yeda Res & Dev Varig transplantation og udvikling af humane hæmopoietiske cellelinjer i normale pattedyr
AU637914B2 (en) 1990-05-03 1993-06-10 Systemix, Inc. Human lymphoid tissue in an immunocompromised host
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
EP0484512A4 (en) 1990-05-25 1993-05-05 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0571525A1 (en) 1991-02-11 1993-12-01 OMMAYA, Ayub K. Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
DE69229254T2 (de) 1991-10-30 1999-09-23 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
CA2103693A1 (en) 1993-08-06 1995-02-07 Steven Gallinger Animal model of the human immune system
CA2195678A1 (en) 1994-07-27 1996-02-08 Joseph A. Borkowski Bradykinin b2 receptor modified transgenic non-human animals
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
CA2284689C (en) 1997-04-09 2009-10-06 Lung-Ji Chang Animal model for evaluation of vaccines
WO2001015521A1 (en) * 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
CA2392740A1 (en) 1999-12-09 2001-06-14 Human Genome Sciences, Inc. Il-6 like polynucleotides, polypeptides, and antibodies
US6864061B2 (en) 2000-09-14 2005-03-08 Genetrol Biotherapeutics, Inc. Method for screening compounds for anti-inflammatory activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030124091A1 (en) 2001-10-26 2003-07-03 Large Scale Biology Corporation Endothelial cell derived hematopoietic growth factor
EP1994824A1 (en) 2001-11-15 2008-11-26 Kirin Pharma Kabushiki Kaisha Chimeric non-human animal
WO2004005496A1 (ja) 2002-07-05 2004-01-15 Kirin Beer Kabushiki Kaisha 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
AU2003278790A1 (en) 2002-09-09 2004-03-29 California Institute Of Technology Methods and compositions for the generation of humanized mice
EP1418185A1 (en) * 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
CN1751236A (zh) * 2002-12-16 2006-03-22 健泰科生物技术公司 表达人cd20的转基因小鼠
KR20050084317A (ko) 2002-12-16 2005-08-26 제넨테크, 인크. 인간 ｃｄ２０ 및(또는) ｃｄ１６을 발현하는 트랜스제닉마우스
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
PT2019683T (pt) 2006-04-25 2017-03-17 Univ California Administração de fatores de crescimento para o tratamento de distúrbios do snc
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
EP2088854A1 (en) 2006-12-05 2009-08-19 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
JP5666903B2 (ja) * 2007-05-23 2015-02-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 導入遺伝子の発現を増強するための方法および組成物
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
WO2009042917A1 (en) 2007-09-28 2009-04-02 The General Hospital Corporation Methods and compositions for antibody production
WO2009097468A2 (en) 2008-01-29 2009-08-06 Kliman Gilbert H Drug delivery devices, kits and methods therefor
AU2013204613A1 (en) 2008-12-24 2013-05-16 The Kingdom of The Netherlands, Represented by The Minister of Health, Welfare and Sport Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
SG176117A1 (en) 2009-06-29 2011-12-29 Ilya B Leskov Non-human mammal model of human hematopoietic cancer
EP2449094A4 (en) 2009-06-29 2013-07-10 Qingfeng Chen METHOD FOR PRODUCING HUMANIZED NON-MAMMAL MAMMALS
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
WO2012040207A2 (en) 2010-09-20 2012-03-29 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
PT4233537T (pt) 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
BR112014008529A2 (pt) 2011-10-28 2017-04-18 Regeneron Pharma il-6 humanizado e receptor de il-6
RU2642319C2 (ru) 2012-09-07 2018-01-24 Йель Юниверсити Генетически модифицированные, не принадлежащие к человеческому роду животные и способ их использования
PT3939423T (pt) 2012-11-05 2024-05-29 Regeneron Pharma Animais não humanos geneticamente modificados e métodos de utilização dos mesmos
KR102407354B1 (ko) 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
SI3138397T1 (sl) 2013-10-15 2019-04-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
MX379268B (es) 2014-05-19 2025-03-11 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
CN107896479B (zh) 2015-04-13 2021-07-13 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法
JP2019519592A (ja) 2016-06-29 2019-07-11 メンロ セラピューティクス インコーポレイテッド 様々な掻痒状態を処置するためのニューロキニン−１アンタゴニストの使用

Also Published As

Publication number Publication date
IL278385B (en) 2021-12-01
AU2012217836A1 (en) 2013-03-28
CN111808879A (zh) 2020-10-23
MX380588B (es) 2025-03-12
IL238781A (en) 2017-08-31
JP2017189180A (ja) 2017-10-19
NZ724014A (en) 2018-12-21
AU2012217836B2 (en) 2015-01-29
KR102585058B1 (ko) 2023-10-05
DK3375284T3 (da) 2023-06-12
EP2675271B1 (en) 2018-06-13
KR20140020865A (ko) 2014-02-19
EP2675271A2 (en) 2013-12-25
IL239350A0 (en) 2015-07-30
CA2826714A1 (en) 2012-08-23
WO2012112544A2 (en) 2012-08-23
IL238781A0 (en) 2015-06-30
IL266886B (en) 2020-11-30
US20130042330A1 (en) 2013-02-14
KR102109172B1 (ko) 2020-05-12
NZ613948A (en) 2015-06-26
IL288167A (en) 2022-01-01
EP4233537A2 (en) 2023-08-30
RU2016104468A3 (es) 2019-06-26
KR20200003241A (ko) 2020-01-08
RU2020126649A (ru) 2022-02-10
CN105861553B (zh) 2020-08-14
JP2014510520A (ja) 2014-05-01
JP6732987B2 (ja) 2020-07-29
MY162984A (en) 2017-07-31
EP4233537A3 (en) 2023-09-13
KR102061143B1 (ko) 2019-12-31
FI3375284T3 (fi) 2023-06-15
EP4233537B1 (en) 2025-07-09
IL253743B (en) 2019-05-30
KR102714361B1 (ko) 2024-10-11
US9655352B2 (en) 2017-05-23
EP2675271A4 (en) 2015-03-18
IL227704A0 (en) 2013-09-30
JP2020168023A (ja) 2020-10-15
PT4233537T (pt) 2025-09-08
RU2730643C2 (ru) 2020-08-24
KR20200054323A (ko) 2020-05-19
KR102256316B1 (ko) 2021-05-28
SG10202008003VA (en) 2020-10-29
US20170273285A1 (en) 2017-09-28
MX2013009406A (es) 2013-12-16
EP3375284B1 (en) 2023-03-29
JP5834097B2 (ja) 2015-12-16
IL266886A (en) 2019-07-31
IL253743A0 (en) 2017-09-28
CN105861553A (zh) 2016-08-17
US20150047061A1 (en) 2015-02-12
JP6505786B2 (ja) 2019-04-24
JP2016039818A (ja) 2016-03-24
IL239350A (en) 2017-12-31
US20250072406A1 (en) 2025-03-06
KR102390850B1 (ko) 2022-04-26
CA2826714C (en) 2022-11-08
ES2948210T3 (es) 2023-09-06
ES3040596T3 (en) 2025-11-03
SG192606A1 (en) 2013-09-30
KR20220054718A (ko) 2022-05-03
CN103547148B (zh) 2016-06-08
JP7181911B2 (ja) 2022-12-01
PT2675271T (pt) 2018-10-11
JP6188765B2 (ja) 2017-08-30
US10785966B2 (en) 2020-09-29
EP3375284A1 (en) 2018-09-19
RU2013142043A (ru) 2015-03-27
RU2577978C2 (ru) 2016-03-20
RU2016104468A (ru) 2018-11-22
DK2675271T3 (en) 2018-08-27
US12127536B2 (en) 2024-10-29
SG10201601067WA (en) 2016-03-30
CN111808879B (zh) 2024-12-31
CN103547148A (zh) 2014-01-29
NZ708040A (en) 2016-10-28
ES2685790T3 (es) 2018-10-11
PT3375284T (pt) 2023-06-28
WO2012112544A3 (en) 2012-11-15
KR20210062718A (ko) 2021-05-31
JP2019122397A (ja) 2019-07-25
DK4233537T3 (da) 2025-08-25
KR20230145500A (ko) 2023-10-17
MX350385B (es) 2017-09-04
US20210112791A1 (en) 2021-04-22
US8847004B2 (en) 2014-09-30
FI4233537T3 (fi) 2025-08-27

Similar Documents

Publication Publication Date Title
MX338971B (es) Ratones de m-csf humanizada.
CY1119283T1 (el) Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii
CY2019008I1 (el) Χρηση τροποποιημενων απο χιμαιρικο αντιγονικο υποδοχεα τ κυτταρων στη θεραπευτικη αγωγη καρκινου
UY33202A (es) Proteínas de unión a cd127
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
CY1119852T1 (el) Σκευασμα αντισωματος και θεραπευτικα σχηματα
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
UY34995A (es) Formulaciones de anticuerpo y proteína
MX2019005251A (es) Animales no humanos geneticamente modificados y metodos de uso de los mismos.
MX369545B (es) Receptor de antígeno químerico y métodos para usarlo.
MX2022001202A (es) Ratones con genes insertados de sirp¿-il15 humanizadas y métodos para usarlos.
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
CR20140352A (es) Anticuerpo anti-epirregulina humanizado y agente terapéutico contra el cáncer que comprende dicho anticuerpo como ingrediente activo
DOP2014000170A (es) Compuestos de imidazopirrolidinona
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
CL2014002342A1 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma.
BR112015014253A2 (pt) produtos de higiene bucal que compreendem um complexo de haleto de aminoácido e zinco tetrabásico
EP2882847A4 (en) NATURAL KILLER CELLS AND ITS USE
UY33421A (es) Proteinas de union al antígeno humanizados
MX382840B (es) Regiones de anticuerpo modificado y sus usos.
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
MX2014013678A (es) Agentes para neutralizacion de influenza.
BR112015014621A2 (pt) Anticorpos anti-h7cr
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19

Legal Events

Date Code Title Description
FG Grant or registration